Fig. 4: Lnc049808 Is a target of miR-101.
From: Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway
A U6, GAPDH, and lnc049808 levels were determined by qRT-PCR. B The predicted binding sites of miR-101 within lnc049808 are shown. C The MS2-based RIP assay confirmed the binding of miR-101 and lnc049808 in 4T1, 891, and BT549 TNBC cells. D Luciferase assay of cells transfected with vectors containing binding sites for miR-101 within lnc049808 (WT) or its mutant (mut). E CCK-8 assay was performed after transfection in 4T1, 891, and BT549 TNBC cells. F A colony formation assay was performed (upper), and the results were quantified (lower). G A Transwell assay was performed (upper), and the results were quantified (lower). H Representative images of xenograft tumors were shown (upper), and tumor weight was quantified (lower, n = 3 per group). I H&E-stained sections of metastatic lung nodules were shown (left), and the number of metastatic nodules was quantified (right, n = 3 per group). *p < 0.05, **p < 0.01.
